s6y

Calidi Biotherapeutics, Inc.

Ticker
CLDI, CLDWW
CIK
1855485
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Calidi Biotherapeutics, Inc., First Light Acquisition Group, Inc.

Financials 22

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 22 financials filings

News 107

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 107 news filings

Ownership 123

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 123 ownership filings

Prospectus 67

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. S-3MEF A new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-3
  5. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  6. S-1 General form of registration statement for all companies including face-amount certificate companies
  7. S-3 Registration statement for specified transactions by certain issuers
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. S-1 General form of registration statement for all companies including face-amount certificate companies

All 67 prospectus filings

Proxies 12

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  3. DEF 14A Definitive proxy statements
  4. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 12 proxies filings

Other 77

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G
  3. SCHEDULE 13D
  4. SCHEDULE 13D
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G
  7. SCHEDULE 13G
  8. EFFECT Notice of Effectiveness
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.

All 77 other filings